Chemotherapy-related cognitive dysfunction (Q37997653)

26 August 2017

Chemotherapy-related cognitive dysfunction (English)

1 reference

26 August 2017

1 reference

Jeffrey S Wefel

1

1 reference

PubMed ID

22453825

26 August 2017

Sanne B Schagen

series ordinal

2

1 reference

26 August 2017

1 June 2012

1 reference

Current Neurology and Neuroscience Reports

26 August 2017

1 reference

26 August 2017

12

1 reference

26 August 2017

267-275

1 reference

26 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s11910-012-0264-9

26 August 2017

0 references

cites work

Cancer therapy-associated CNS neuropathology: an update and review of the literature.

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Capecitabine-induced multifocal leukoencephalopathy: a report of five cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Neurologic complications of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Radiation therapy of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Potential mechanisms for chemotherapy-induced impairments in cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Neurological complications of radiotherapy and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive function in breast cancer patients receiving adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

'Chemobrain' in breast carcinoma?: a prologue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

The effects of adjuvant chemotherapy on cognition in women with breast cancer--preliminary results of an observational longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive impairment associated with adjuvant therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive function in breast cancer patients prior to adjuvant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: 'subjective' complaints and 'objective' neuropsychological test results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive functioning in breast cancer survivors: a controlled comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Regional brain activation during verbal declarative memory in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive impairments associated with breast cancer treatments: results from a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Predictors of cognitive decline after chemotherapy in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Prechemotherapy alterations in brain function in women with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive speed of processing and functional declines in older cancer survivors: an analysis of data from the ACTIVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Prefrontal cortex and executive function impairments in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Candidate mechanisms for chemotherapy-induced cognitive changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Clinical trial end points for high-grade glioma: the evolving landscape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

5-fluorouracil-induced leukoencephalopathy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

The blood-brain barrier and cancer: transporters, treatment, and Trojan horses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0264-9

Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study

21 January 2018

1 reference

12 December 2020

MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma.

1 reference

12 December 2020

Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy

1 reference

12 December 2020

Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target

1 reference

12 December 2020

Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an FMRI study

1 reference

12 December 2020

Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy

1 reference

12 December 2020

Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging

1 reference

12 December 2020

Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects

1 reference

12 December 2020

Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging

1 reference

12 December 2020

Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study.

1 reference

12 December 2020

Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery

1 reference

12 December 2020

Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer

1 reference

12 December 2020

White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy.

1 reference

12 December 2020

Cognitive functions and elderly cancer patients receiving anticancer treatment: A prospective study

1 reference

12 December 2020

10.1007/S11910-012-0264-9

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22453825